William Blair Forecasts NeoGenomics Q1 Earnings

NeoGenomics, Inc. (NASDAQ:NEO) – William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of NeoGenomics in a report issued on Tuesday, February 18th. William Blair analyst A. Brackmann expects that the medical research company will post earnings per share of $0.00 for the quarter. The consensus estimate for NeoGenomics’ current full-year earnings is ($0.05) per share. William Blair also issued estimates for NeoGenomics’ Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at $0.03 EPS.

NEO has been the topic of a number of other reports. Benchmark downgraded NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. The Goldman Sachs Group dropped their price target on NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Jefferies Financial Group started coverage on NeoGenomics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price target on the stock. Bank of America dropped their price target on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday. Finally, Needham & Company LLC dropped their price target on NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.80.

NeoGenomics Stock Performance

NEO stock opened at $11.86 on Friday. The company has a market cap of $1.52 billion, a P/E ratio of -19.13 and a beta of 1.23. NeoGenomics has a 1 year low of $10.69 and a 1 year high of $19.11. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. The stock’s fifty day moving average price is $15.28 and its 200-day moving average price is $15.49.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The business had revenue of $172.00 million for the quarter, compared to analysts’ expectations of $173.40 million.

Hedge Funds Weigh In On NeoGenomics

Institutional investors have recently bought and sold shares of the stock. Creative Planning raised its holdings in NeoGenomics by 42.3% during the third quarter. Creative Planning now owns 23,547 shares of the medical research company’s stock valued at $347,000 after acquiring an additional 7,004 shares during the period. Blue Trust Inc. raised its holdings in NeoGenomics by 42.3% during the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 987 shares during the period. Nisa Investment Advisors LLC raised its holdings in NeoGenomics by 5.0% during the third quarter. Nisa Investment Advisors LLC now owns 45,104 shares of the medical research company’s stock valued at $665,000 after acquiring an additional 2,166 shares during the period. Fernwood Investment Management LLC raised its holdings in NeoGenomics by 1.0% during the third quarter. Fernwood Investment Management LLC now owns 89,500 shares of the medical research company’s stock valued at $1,320,000 after acquiring an additional 900 shares during the period. Finally, Los Angeles Capital Management LLC bought a new stake in NeoGenomics during the third quarter valued at about $1,101,000. 98.50% of the stock is owned by institutional investors.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.